Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04883138 · ClinicalTrials.gov registry record · Phase 1
Recombinant Hyperimmune Polyclonal Antibody (GIGA-2050) in COVID-19 Patients
A Phase 1 study, sponsored by GigaGen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT04883138 is a Phase 1 study that was terminated before completion, run by GigaGen. The registered enrollment target is 3 participants.
The verdict
NCT04883138, a Phase 1 study, was terminated before completion, sponsored by GigaGen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of single ascending IV dose administrations of GIGA-2050 in patients hospitalized with COVID-19.
Interventions
- DRUG GIGA-2050
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2021-05-24 |
| Est. Completion | 2022-01-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04883138
The ClinicalTrials.gov registry entry for NCT04883138 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GigaGen, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GIGA-2050 is the first listed.
NCT04883138 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04883138 about?
NCT04883138 is a clinical study titled "Recombinant Hyperimmune Polyclonal Antibody (GIGA-2050) in COVID-19 Patients". The purpose of this study is to evaluate the safety and tolerability of single ascending IV dose administrations of GIGA-2050 in patients hospitalized with COVID-19.
What is the current status of trial NCT04883138?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2021-05-24. Estimated completion is 2022-01-11.
What interventions are being tested in trial NCT04883138?
The interventions under investigation include: GIGA-2050 (DRUG).
Who is sponsoring clinical trial NCT04883138?
This trial is sponsored by GigaGen, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.